Across TCGA pan-cancer cohorts, RNU7-60P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RNU7-60P’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RNU7-60P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU7-60P is over-expressed in tumor.
PRAD are the cancer types where RNU7-60P tumor–normal differential expression is most reproducible.